0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
NSAIDs (Non-steroidal Anti-inflammatory Drugs) Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

NSAIDs (Non-steroidal Anti-inflammatory Drugs) Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00 – $ 8,900.00

NSAIDs Market: By Molecule Type (Ibuprofen, Aspirin, Paracetamol, Diclofenac and Diclofenac Others), By Formulation (Tablets, Capsules, Suspension, Topical Preparations and Others), and Geography

 

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:
Report

Description

Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Size was valued at USD 2,603 million in 2021 and is poised to grow at a significant CAGR of 0.8% over 2022-2028. Patients with chronic inflammatory arthritis frequently take nonsteroidal anti-inflammatory drugs (NSAIDs). The market for NSAIDs is expected to grow faster as the incidence of arthritis rises. Because of their ability to block prostaglandin formation at the level of the cyclooxygenase enzyme, they are powerful anti-inflammatory and analgesic. In January 2021, NSAIDs have several medications on the market, with many more in the works. Celebrex, an oral drug intended to treat inflammation and discomfort caused by ankylosing spondylitis and other illnesses, was approved by the US Food and Drug Administration. Osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea are among the conditions for which the generic medication is prescribed.

Recent Market Developments:

In May 2019, according to Perrigo Company plc, the FDA has approved an Abbreviated New Drug Application (ANDA) for Voltaren Gel.

In April 2018: The USFDA authorized Strides Shasun’s generic Ibuprofen capsules, 200 mg. They are intended to alleviate pain. Pfizer Inc.’s Advil Liqui-Gels 200 mg is a generic version.

NSAIDs Market

MARKET SUMMARY
-
0.8% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 0.8%
  • Largest Market– Asia-Pacific
  • Fastest Growing Market– North-America

NSAIDs Market

  • The NSAIDs market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The NSAIDs market is segmented based on molecule type, formulation, and geography.
Key Players
  • Bayer AG
  • AstraZeneca
  • Zyla Life Sciences
  • Horizon Therapeutics plc
NSAIDs Market

Dynamics

One of the major reasons driving market expansion is the rising prevalence of pain and inflammation-causing disorders. The use of these medications to treat acute and chronic pain is gradually increasing. Ibuprofen and diclofenac are two of the most widely recommended pain relievers. The governments of several countries are working to lower the cost of detecting and treating chronic pain. NSAIDs, on the other hand, can induce dizziness, stomach problems, ulcers, and allergic reactions, among other things. It can suffocate market growth.

North-America Got Significant Share

NSAIDs Market

The NSAIDs market in North America is likely to hold the moderate revenue share of xx% in 2021 and in the following years, it is predicted to increase at a rapid rate due to the strategic presence of large manufacturers, the rising prevalence of arthritis, and greater research. Market companies in the region are constantly concentrating on the development of novel medications to address these indications with NSAIDs, as well as a variety of tactics to develop better drugs with fewer side effects. Europe, on the other hand, is likely to continue to rise steadily, owing to advantageous health reimbursement systems, a higher frequency of migraine, and strong government assistance.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
NSAIDs Market Segmentation

segmentation-block-image

Molecule Type

    • Ibuprofen
    • Aspirin
    • Paracetamol
    • Diclofenac
    • Others
segmentation-block-image

formulation

    • Tablets
    • Capsules
    • Suspension
    • Topical Preparations
    • Others
segmentation-block-image

By Geography

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA
Location

GEOGRAPHY

Frequently Asked Questions

The NSAIDs Market is projected to expand at a CAGR of 5.6% during the forecast period.

Mitsubishi Electric Corporation (Tokyo, Japan), Trane (Dublin, Ireland), Carrier Corporation (Florida, U.S.), LG Electronics (Seoul, Korea), Daikin Industries, Ltd. (Osaka, Japan)

Asia-Pacific is the fastest-growing region for NSAIDs Market

Report

Company Profile

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • AstraZeneca
  • Zyla Life Sciences
  • Horizon Therapeutics plc

Description

Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Size was valued at USD 2,603 million in 2021 and is poised to grow at a significant CAGR of 0.8% over 2022-2028. Patients with chronic inflammatory arthritis frequently take nonsteroidal anti-inflammatory drugs (NSAIDs). The market for NSAIDs is expected to grow faster as the incidence of arthritis rises. Because of their ability to block prostaglandin formation at the level of the cyclooxygenase enzyme, they are powerful anti-inflammatory and analgesic. In January 2021, NSAIDs have several medications on the market, with many more in the works. Celebrex, an oral drug intended to treat inflammation and discomfort caused by ankylosing spondylitis and other illnesses, was approved by the US Food and Drug Administration. Osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea are among the conditions for which the generic medication is prescribed.

Recent Market Developments:

In May 2019, according to Perrigo Company plc, the FDA has approved an Abbreviated New Drug Application (ANDA) for Voltaren Gel.

In April 2018: The USFDA authorized Strides Shasun’s generic Ibuprofen capsules, 200 mg. They are intended to alleviate pain. Pfizer Inc.’s Advil Liqui-Gels 200 mg is a generic version.

Reviews

There are no reviews yet.

Be the first to review “NSAIDs (Non-steroidal Anti-inflammatory Drugs) Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+